Literature DB >> 7121665

Citrate in urine and serum and associated variables in subgroups of urolithiasis. Results from an outpatient stone clinic.

P O Schwille, D Scholz, K Schwille, R Leutschaft, I Goldberg, A Sigel.   

Abstract

Outpatient renal stone formers belonging to the established urolithiasis subgroups and controls were examined with respect to urinary and serum citrate (Cit) and several associated variables. Only in the normocalciuric majority of calcium and in uric acid stone formers was Cit in 24-hour urine decreased, but was normal in 2-hour fasting morning, and in 3-hour postprandial urine following a Cit-free test meal. Serum Cit was elevated in normocalciuria, renal and resorptive hypercalciuria. This Cit constellation was associated with either normal (absorptive, renal hypercalciuria) or low (normocalciuria, uric acid stone formers) parathyroid gland function as assessed by serum parathyroid hormone and nephrogenous urinary cyclic AMP, except in patients with primary hyperparathyroidism. In 2-hour morning urine the magnesium/creatinine ratio (normocalciuria) and ammonia excretion (uric acid stone formers) were decreased, while ammonia in 24-hour urine was low in all stone formers. It is suggested that Cit metabolism is altered in renal stone disease in general, and that in normocalciuria, stone inhibitors (Cit; magnesium) may be deficient.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7121665     DOI: 10.1159/000182646

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  12 in total

Review 1.  Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation.

Authors:  R L Ryall
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  The importance of diet in urinary stones.

Authors:  W Vahlensieck
Journal:  Urol Res       Date:  1986

3.  Urinary excretion of calcium, magnesium, oxalate and citrate in duodenal ulcer patients. Preliminary results before and up to five years after highly selective vagotomy.

Authors:  P O Schwille; D Scholz; E Hanisch; E Zeuner; H Schwendtner; B Husemann; E Mühe; A Sigel
Journal:  Klin Wochenschr       Date:  1983-09-01

4.  Parathyroid gland function in subgroups of metabolically mediated urolithiasis as evaluated by serum parathyroid hormone, and urinary and nephrogenous cyclic nucleotides.

Authors:  P O Schwille; D Scholz; K Schwille; W Engelhardt; B Schreiber; I Goldberg; A Sigel
Journal:  Klin Wochenschr       Date:  1982-03-01

5.  Acute oral alkali citrate load in healthy humans--response of blood and urinary citrate, mineral metabolism, and factors related to stone formation.

Authors:  P O Schwille; J H Weippert; W Bausch; G Rümenapf
Journal:  Urol Res       Date:  1985

6.  Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium citrate administered over the short-, medium- and long-term medication of male stone patients.

Authors:  P O Schwille; U Herrmann; C Wolf; I Berger; R Meister
Journal:  Urol Res       Date:  1992

7.  Absence or decreased endogenous thiosulfaturia: a cause of recurrent calcium nephrolithiasis.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 8.  Urine citrate and renal stone disease.

Authors:  H Goldberg; L Grass; R Vogl; A Rapoport; D G Oreopoulos
Journal:  CMAJ       Date:  1989-08-01       Impact factor: 8.262

9.  Determination of GOT activity on nucleation and crystal growth of calcium oxalate.

Authors:  R Azoury; S Sarig; N Garti; S Perlberg; A D Randolph; G W Drach
Journal:  Urol Res       Date:  1984

10.  Citrate and recurrent idiopathic calcium urolithiasis. A longitudinal pilot study on the metabolic effects of oral potassium sodium citrate administered as short-, medium- and long-term to male stone patients.

Authors:  U Herrmann; P O Schwille; H Schwarzlaender; I Berger; G Hoffmann
Journal:  Urol Res       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.